<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34630378</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>An Albumin-Binding Domain Peptide Confers Enhanced Immunoprotection Against Viral Myocarditis by CVB3 VP1 Vaccine.</ArticleTitle><Pagination><StartPage>666594</StartPage><MedlinePgn>666594</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">666594</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2021.666594</ELocationID><Abstract><AbstractText><i>Coxsackievirus B3 (CVB3)</i>-induced viral myocarditis is a common clinical cardiovascular disease without effective available vaccine. In this study, we tried to potentiate the immunoprotection efficacy of our previous <i>CVB3</i>-specific VP1 protein vaccine by introducing a streptococcal protein G-derived, draining lymph nodes (dLNs)-targeting albumin-binding domain (ABD) peptide. We found that compared with the original VP1 vaccine, ABD-fused VP1 (ABD-VP1) vaccine gained the new ability to efficiently bind murine albumin both <i>in vitro</i> and <i>in vivo</i>, possessed a much longer serum half-life in serum and exhibited more abundance in the dLNs after immunization. Accordingly, ABD-VP1 immunization not only significantly facilitated the enrichment and maturation of dendritic cells (DCs), induced higher percentages of IFN<i>-&#x3b3;<sup>+</sup></i> CD8 <i><sup>+</sup></i> cells in the dLNs, but also robustly promoted VP1-induced T cell proliferation and cytotoxic T lymphocyte (CTL) responses in the spleens. More importantly, ABD-VP1 also elicited higher percentages of protective CD44<sup>hi</sup> CD62L<sup>hi</sup> memory T cells in dLNs and spleens. Consequently, obvious protective effect against viral myocarditis was conferred by ABD-VP1 vaccine compared to the VP1 vaccine, reflected by the less body weight loss, improved cardiac function, alleviated cardiac histomorphological changes and an increased 28-day survival rate. Our results indicated that the ABD might be a promising immune-enhancing regime for vaccine design and development.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Gao, Yue and Xiong.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Science, Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Science, Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Sidong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Science, Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C034284">IgG Fc-binding protein, Streptococcus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000627674">VP1 protein, enterovirus B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001426" MajorTopicYN="N">Bacterial Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="N">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="N">Myocarditis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054730" MajorTopicYN="N">Protein Interaction Domains and Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ABD</Keyword><Keyword MajorTopicYN="N">CTL</Keyword><Keyword MajorTopicYN="N">Coxsackievirus B3</Keyword><Keyword MajorTopicYN="N">draining lymph nodes</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword><Keyword MajorTopicYN="N">viral myocarditis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>11</Day><Hour>5</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34630378</ArticleId><ArticleId IdType="pmc">PMC8492941</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.666594</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Van Linthout S, Savvatis K, Miteva K, Peng J, Ringe J, Warstat K, et al. . Mesenchymal Stem Cells Improve Murine Acute Coxsackievirus B3-Induced Myocarditis. Eur Heart J (2011) 32(17):2168&#x2013;78. doi:&#xa0;10.1093/eurheartj/ehq467</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehq467</ArticleId><ArticleId IdType="pmc">PMC3164101</ArticleId><ArticleId IdType="pubmed">21183501</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang Z, Wang ZH, Deng LH, Zheng Q, Zheng GQ, Wang Y. Astragaloside IV Exerts Cardioprotection in Animal Models of Viral Myocarditis: A Preclinical Systematic Review and Meta-Analysis. Front Pharmacol (2019) 10:1388. doi:&#xa0;10.3389/fphar.2019.01388</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.01388</ArticleId><ArticleId IdType="pmc">PMC6892970</ArticleId><ArticleId IdType="pubmed">31849654</ArticleId></ArticleIdList></Reference><Reference><Citation>Sole MJ, Liu P. Viral Myocarditis: A Paradigm for Understanding the Pathogenesis and Treatment of Dilated Cardiomyopathy. J Am Coll Cardiol (1993) 22(4 Suppl A):99A&#x2013;105A. doi:&#xa0;10.1016/0735-1097(93)90470-l</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0735-1097(93)90470-l</ArticleId><ArticleId IdType="pubmed">8376702</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubba L, Broberg EK, Jasir A, Simmonds P, Harvala H. Enterovirus Study C. Circulation of non-Polio Enteroviruses in 24 EU and EEA Countries Between 2015 and 2017: A Retrospective Surveillance Study. Lancet Infect Dis (2020) 20(3):350&#x2013;61. doi:&#xa0;10.1016/S1473-3099(19)30566-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(19)30566-3</ArticleId><ArticleId IdType="pubmed">31870905</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack A, Kontorovich AR, Fuster V, Dec GW. Viral Myocarditis&#x2013;Diagnosis, Treatment Options, and Current Controversies. Nat Rev Cardiol (2015) 12(11):670&#x2013;80. doi:&#xa0;10.1038/nrcardio.2015.108</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2015.108</ArticleId><ArticleId IdType="pubmed">26194549</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairley CK, Ryan M, Wall PG, Weinberg J. The Organisms Reported to Cause Infective Myocarditis and Pericarditis in England and Wales. J Infect (1996) 32(3):223&#x2013;5. doi:&#xa0;10.1016/s0163-4453(96)80023-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0163-4453(96)80023-5</ArticleId><ArticleId IdType="pubmed">8793712</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Li Y, Peng T, Aasa M, Zhang L, Yang Y, et al. . Localization of Enteroviral Antigen in Myocardium and Other Tissues From Patients With Heart Muscle Disease by an Improved Immunohistochemical Technique. J Histochem Cytochem (2000) 48(5):579&#x2013;84. doi:&#xa0;10.1177/002215540004800501</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/002215540004800501</ArticleId><ArticleId IdType="pubmed">10769041</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin L, Chai D, Yue Y, Dong C, Xiong S. AIM2 Co-Immunization With VP1 is Associated With Increased Memory CD8 T Cells and Mounts Long Lasting Protection Against Coxsackievirus B3 Challenge. Front Cell Infect Microbiol (2017) 7:247. doi:&#xa0;10.3389/fcimb.2017.00247</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2017.00247</ArticleId><ArticleId IdType="pmc">PMC5462951</ArticleId><ArticleId IdType="pubmed">28642849</ArticleId></ArticleIdList></Reference><Reference><Citation>Maghsoudi N, Khalilpour A, Kamali M, Zeinoddini M. Cloning and Expression of Coxsakievirus B3 Viral Protein-1 in E. Coli. Iranian Biomed J (2007) 11(3):147&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">18051774</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Shen Y, Wang LX, Xu CF, Zheng XJ, Xiong SD. [Protective Immunoresponse to CVB3 Induced by Gene Immunization With Pcdna3-VP1]. Xi bao yu fen zi mian yi xue za zhi = Chin J Cell Mol Immunol (2003) 19(3):239&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15155081</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Zhao P, Dong S, Xu T, He X, Chen M. An Albumin-Binding Polypeptide Both Targets Cytotoxic T Lymphocyte Vaccines to Lymph Nodes and Boosts Vaccine Presentation by Dendritic Cells. Theranostics (2018) 8(1):223&#x2013;36. doi:&#xa0;10.7150/thno.21691</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.21691</ArticleId><ArticleId IdType="pmc">PMC5743471</ArticleId><ArticleId IdType="pubmed">29290804</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeanbart L, Ballester M, de Titta A, Corthesy P, Romero P, Hubbell JA, et al. . Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes. Cancer Immunol Res (2014) 2(5):436&#x2013;47. doi:&#xa0;10.1158/2326-6066.CIR-14-0019-T</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0019-T</ArticleId><ArticleId IdType="pubmed">24795356</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Wang Q, Sun X. Lymph Node Targeting Strategies to Improve Vaccination Efficacy. J Controlled release: Off J Controlled Release Soc (2017) 267:47&#x2013;56. doi:&#xa0;10.1016/j.jconrel.2017.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2017.08.009</ArticleId><ArticleId IdType="pubmed">28818619</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsadek B, Kratz F. Impact of Albumin on Drug Delivery&#x2013;New Applications on the Horizon. J Controlled release: Off J Controlled Release Soc (2012) 157(1):4&#x2013;28. doi:&#xa0;10.1016/j.jconrel.2011.09.069</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2011.09.069</ArticleId><ArticleId IdType="pubmed">21959118</ArticleId></ArticleIdList></Reference><Reference><Citation>Kratz F. Albumin as a Drug Carrier: Design of Prodrugs, Drug Conjugates and Nanoparticles. J Controlled release: Off J Controlled Release Soc (2008) 132(3):171&#x2013;83. doi:&#xa0;10.1016/j.jconrel.2008.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2008.05.010</ArticleId><ArticleId IdType="pubmed">18582981</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudarha RR, Sawant KK. Albumin Based Versatile Multifunctional Nanocarriers for Cancer Therapy: Fabrication, Surface Modification, Multimodal Therapeutics and Imaging Approaches. Materials Sci Eng C Materials Biol Appl (2017) 81:607&#x2013;26. doi:&#xa0;10.1016/j.msec.2017.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msec.2017.08.004</ArticleId><ArticleId IdType="pubmed">28888016</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Lou C, Wengel J, Howard KA. Albumin-Binding Fatty Acid-Modified Gapmer Antisense Oligonucleotides for Modulation of Pharmacokinetics. Methods Mol Biol (2020) 2176:163&#x2013;74. doi:&#xa0;10.1007/978-1-0716-0771-8_12</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-0771-8_12</ArticleId><ArticleId IdType="pubmed">32865790</ArticleId></ArticleIdList></Reference><Reference><Citation>Czub MP, Boulton AM, Rastelli EJ, Tasker NR, Maskrey TS, Blanco IK, et al. . Structure of the Complex of an Iminopyridinedione Protein Tyrosine Phosphatase 4A3 Phosphatase Inhibitor With Human Serum Albumin. Mol&#xa0;Pharmacol (2020) 98(6):648&#x2013;57. doi:&#xa0;10.1124/molpharm.120.000131</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/molpharm.120.000131</ArticleId><ArticleId IdType="pmc">PMC7658597</ArticleId><ArticleId IdType="pubmed">32978326</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauri S, Jakubiak P, Fueth M, Dengl S, Belli S, Alvarez-Sanchez R, et al. . Understanding the Half-Life Extension of Intravitreally Administered Antibodies Binding to Ocular Albumin. Pharmaceutics (2020) 12(9):810. doi:&#xa0;10.3390/pharmaceutics12090810</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12090810</ArticleId><ArticleId IdType="pmc">PMC7559355</ArticleId><ArticleId IdType="pubmed">32858986</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrokova H, Masek J, Kuchar M, Viteckova Wunschova A, Stikarova J, Bartheldyova E, et al. . Targeting Human Thrombus by Liposomes Modified With Anti-Fibrin Protein Binders. Pharmaceutics (2019) 11(12):642. doi:&#xa0;10.3390/pharmaceutics11120642</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics11120642</ArticleId><ArticleId IdType="pmc">PMC6955937</ArticleId><ArticleId IdType="pubmed">31810280</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas LA, Condezo GN, Moreno R, Fajardo CA, Arias-Badia M, San Martin C, et al. . Albumin-Binding Adenoviruses Circumvent Pre-Existing Neutralizing Antibodies Upon Systemic Delivery. J Controlled Release: Off J Controlled Release Soc (2016) 237:78&#x2013;88. doi:&#xa0;10.1016/j.jconrel.2016.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2016.07.004</ArticleId><ArticleId IdType="pubmed">27388756</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi X, Xiong S. Intein-Mediated Backbone Cyclization of VP1 Protein Enhanced Protection of CVB3-Induced Viral Myocarditis. Sci Rep (2017) 7:41485. doi:&#xa0;10.1038/srep41485</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep41485</ArticleId><ArticleId IdType="pmc">PMC5288654</ArticleId><ArticleId IdType="pubmed">28148910</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell AE, Zhang K, Sanyal M, Tang S, Weidenbacher PA, Li S, et al. . A Single Immunization With Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses Against SARS-CoV-2 in Mice. ACS Cent Sci (2021) 7(1):183&#x2013;99. doi:&#xa0;10.1021/acscentsci.0c01405</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.0c01405</ArticleId><ArticleId IdType="pmc">PMC7805605</ArticleId><ArticleId IdType="pubmed">33527087</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Yue Y, Dong C, Li X, Xu W, Xiong S. Mucosal Immunization With High-Mobility Group Box 1 in Chitosan Enhances DNA Vaccine-Induced Protection Against Coxsackievirus B3-Induced Myocarditis. Clin Vaccine Immunol: CVI (2013) 20(11):1743&#x2013;51. doi:&#xa0;10.1128/CVI.00466-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00466-13</ArticleId><ArticleId IdType="pmc">PMC3837774</ArticleId><ArticleId IdType="pubmed">24027262</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue Y, Gui J, Ai W, Xu W, Xiong S. Direct Gene Transfer With IP-10 Mutant Ameliorates Mouse CVB3-Induced Myocarditis by Blunting Th1 Immune Responses. PloS One (2011) 6(3):e18186. doi:&#xa0;10.1371/journal.pone.0018186</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0018186</ArticleId><ArticleId IdType="pmc">PMC3062568</ArticleId><ArticleId IdType="pubmed">21445362</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Yue Y, Sun T, Wu X, Xiong S. Transmissible Endoplasmic Reticulum Stress From Myocardiocytes to Macrophages is Pivotal for the Pathogenesis of CVB3-Induced Viral Myocarditis. Sci Rep (2017) 7:42162. doi:&#xa0;10.1038/srep42162</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42162</ArticleId><ArticleId IdType="pmc">PMC5296968</ArticleId><ArticleId IdType="pubmed">28176833</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker P, Kloner RA, Boughner DR, Pickering JG. Quantitative Assessment of Myocardial Collagen With Picrosirius Red Staining and Circularly Polarized Light. Basic Res Cardiol (1994) 89(5):397&#x2013;410. doi:&#xa0;10.1007/BF00788278</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00788278</ArticleId><ArticleId IdType="pubmed">7535519</ArticleId></ArticleIdList></Reference><Reference><Citation>Laucella S, Salcedo R, Castanos-Velez E, Riarte A, De Titto EH, Patarroyo M, et al. . Increased Expression and Secretion of ICAM-1 During Experimental Infection With Trypanosoma Cruzi. Parasite Immunol (1996) 18(5):227&#x2013;39. doi:&#xa0;10.1046/j.1365-3024.1996.d01-95.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-3024.1996.d01-95.x</ArticleId><ArticleId IdType="pubmed">9229375</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronkite DA, Strutt TM. The Regulation of Inflammation by Innate and Adaptive Lymphocytes. J Immunol Res (2018) 2018:1467538. doi:&#xa0;10.1155/2018/1467538</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/1467538</ArticleId><ArticleId IdType="pmc">PMC6016164</ArticleId><ArticleId IdType="pubmed">29992170</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaender S, Mar KB, Michailidis E, Kratzel A, Hirt D, V&#x2019;Kovski P, et al. . LY6E Impairs Coronavirus Fusion and Confers Immune Control of Viral Disease. bioRxiv: Preprint Server Biol (2020) 5(11):1330&#x2013;9. doi:&#xa0;10.1101/2020.03.05.979260</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.05.979260</ArticleId><ArticleId IdType="pmc">PMC7916999</ArticleId><ArticleId IdType="pubmed">32704094</ArticleId></ArticleIdList></Reference><Reference><Citation>Baptista AP, Gola A, Huang Y, Milanez-Almeida P, Torabi-Parizi P, Urban JF, Jr., et al. . The Chemoattractant Receptor Ebi2 Drives Intranodal Naive CD4(+) T Cell Peripheralization to Promote Effective Adaptive Immunity. Immunity (2019) 50(5):1188&#x2013;201.e6. doi:&#xa0;10.1016/j.immuni.2019.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.04.001</ArticleId><ArticleId IdType="pubmed">31053504</ArticleId></ArticleIdList></Reference><Reference><Citation>Macedo R, Rochefort J, Guillot-Delost M, Tanaka K, Le Moignic A, Noizat C, et al. . Intra-Cheek Immunization as a Novel Vaccination Route for Therapeutic Vaccines of Head and Neck Squamous Cell Carcinomas Using Plasmo Virus-Like Particles. Oncoimmunology (2016) 5(7):e1164363. doi:&#xa0;10.1080/2162402X.2016.1164363</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2016.1164363</ArticleId><ArticleId IdType="pmc">PMC5006902</ArticleId><ArticleId IdType="pubmed">27622018</ArticleId></ArticleIdList></Reference><Reference><Citation>Cioncada R, Maddaluno M, Vo HTM, Woodruff M, Tavarini S, Sammicheli C, et al. . Vaccine Adjuvant MF59 Promotes the Intranodal Differentiation of Antigen-Loaded and Activated Monocyte-Derived Dendritic Cells. PloS One (2017) 12(10):e0185843. doi:&#xa0;10.1371/journal.pone.0185843</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0185843</ArticleId><ArticleId IdType="pmc">PMC5663329</ArticleId><ArticleId IdType="pubmed">29088224</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Keeffe M, Mok WH, Radford KJ. Human Dendritic Cell Subsets and Function in Health and Disease. Cell Mol Life Sci (2015) 72(22):4309&#x2013;25. doi:&#xa0;10.1007/s00018-015-2005-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-015-2005-0</ArticleId><ArticleId IdType="pmc">PMC11113503</ArticleId><ArticleId IdType="pubmed">26243730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederman MM, Margolis L. The Lymph Node in HIV Pathogenesis. Semin Immunol (2008) 20(3):187&#x2013;95. doi:&#xa0;10.1016/j.smim.2008.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2008.06.001</ArticleId><ArticleId IdType="pmc">PMC2577760</ArticleId><ArticleId IdType="pubmed">18620868</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao D, Chen Y, Liu L. Engineered Therapeutic Nanovaccine Against Chronic Hepatitis B Virus Infection. Biomaterials (2021) 269:120674. doi:&#xa0;10.1016/j.biomaterials.2021.120674</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2021.120674</ArticleId><ArticleId IdType="pubmed">33486345</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, De Koker S, De Geest BG. Engineering Strategies for Lymph Node Targeted Immune Activation. Accounts Chem Res (2020) 53(10):2055&#x2013;67. doi:&#xa0;10.1021/acs.accounts.0c00260</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.accounts.0c00260</ArticleId><ArticleId IdType="pubmed">32910636</ArticleId></ArticleIdList></Reference><Reference><Citation>Schudel A, Francis DM, Thomas SN. Material Design for Lymph Node Drug Delivery. Nat Rev Materials (2019) 4(6):415&#x2013;28. doi:&#xa0;10.1038/s41578-019-0110-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41578-019-0110-7</ArticleId><ArticleId IdType="pmc">PMC7286627</ArticleId><ArticleId IdType="pubmed">32523780</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorzi A, Middendorp SJ, Wilbs J, Deyle K, Heinis C. Acylated Heptapeptide Binds Albumin With High Affinity and Application as Tag Furnishes Long-Acting Peptides. Nat Commun (2017) 8:16092. doi:&#xa0;10.1038/ncomms16092</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms16092</ArticleId><ArticleId IdType="pmc">PMC5520048</ArticleId><ArticleId IdType="pubmed">28714475</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdallah M, Mullertz OO, Styles IK, Morsdorf A, Quinn JF, Whittaker MR, et al. . Lymphatic Targeting by Albumin-Hitchhiking: Applications and Optimisation. J Control Release (2020) 327:117&#x2013;28. doi:&#xa0;10.1016/j.jconrel.2020.07.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.07.046</ArticleId><ArticleId IdType="pubmed">32771478</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Yang H, Jia D, Nie Q, Cai H, Fan Q, et al. . Fusion to an Albumin-Binding Domain With a High Affinity for Albumin Extends the Circulatory Half-Life and Enhances the In Vivo Antitumor Effects of Human TRAIL. J Controlled Release: Off J Controlled Release Soc (2016) 228:96&#x2013;106. doi:&#xa0;10.1016/j.jconrel.2016.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2016.03.004</ArticleId><ArticleId IdType="pubmed">26951928</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep D, Cameron J, Evans LR. Albumin as a Versatile Platform for Drug Half-Life Extension. Biochim Biophys Acta (2013) 1830(12):5526&#x2013;34. doi:&#xa0;10.1016/j.bbagen.2013.04.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagen.2013.04.023</ArticleId><ArticleId IdType="pubmed">23639804</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyer TJ, Zmolek AC, Irvine DJ. Beyond Antigens and Adjuvants: Formulating Future Vaccines. J Clin Invest (2016) 126(3):799&#x2013;808. doi:&#xa0;10.1172/JCI81083</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI81083</ArticleId><ArticleId IdType="pmc">PMC4767337</ArticleId><ArticleId IdType="pubmed">26928033</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson MU, Frick IM, Nilsson H, Kraulis PJ, Hober S, Jonasson P, et al. . Structure, Specificity, and Mode of Interaction for Bacterial Albumin-Binding Modules. J Biol Chem (2002) 277(10):8114&#x2013;20. doi:&#xa0;10.1074/jbc.M109943200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109943200</ArticleId><ArticleId IdType="pubmed">11751858</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilvebrant J, Hober S. The Albumin-Binding Domain as a Scaffold for Protein Engineering. Comput Struct Biotechnol J (2013) 6:e201303009. doi:&#xa0;10.5936/csbj.201303009</Citation><ArticleIdList><ArticleId IdType="doi">10.5936/csbj.201303009</ArticleId><ArticleId IdType="pmc">PMC3962080</ArticleId><ArticleId IdType="pubmed">24688717</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Dong S, Zhao P, He X, Chen M. Direct Loading of CTL Epitopes Onto MHC Class I Complexes on Dendritic Cell Surface in Vivo . Biomaterials (2018) 182:92&#x2013;103. doi:&#xa0;10.1016/j.biomaterials.2018.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2018.08.008</ArticleId><ArticleId IdType="pmc">PMC6218175</ArticleId><ArticleId IdType="pubmed">30107273</ArticleId></ArticleIdList></Reference><Reference><Citation>Newey RM. Coping With Blindness. Veterinary Rec (1989) 124(4):104. doi:&#xa0;10.1136/vr.124.4.104</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/vr.124.4.104</ArticleId><ArticleId IdType="pubmed">2929080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J, Bera TK, Liu XF, Zhou Q, Onda M, Ho M, et al. . Recombinant Immunotoxins With Albumin-Binding Domains Have Long Half-Lives and High Antitumor Activity. Proc Natl Acad Sci U S A (2018) 115(15):E3501&#x2013;E8. doi:&#xa0;10.1073/pnas.1721780115</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1721780115</ArticleId><ArticleId IdType="pmc">PMC5899471</ArticleId><ArticleId IdType="pubmed">29581296</ArticleId></ArticleIdList></Reference><Reference><Citation>Stork R, Muller D, Kontermann RE. A Novel Tri-Functional Antibody Fusion Protein With Improved Pharmacokinetic Properties Generated by Fusing a Bispecific Single-Chain Diabody With an Albumin-Binding Domain From Streptococcal Protein G. Protein Eng Design Selection: PEDS (2007) 20(11):569&#x2013;76. doi:&#xa0;10.1093/protein/gzm061</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/protein/gzm061</ArticleId><ArticleId IdType="pubmed">17982179</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu G, Lynn GM, Jacobson O, Chen K, Liu Y, Zhang H, et al. . Albumin/Vaccine Nanocomplexes That Assemble In Vivo for Combination Cancer Immunotherapy. Nat Commun (2017) 8(1):1954. doi:&#xa0;10.1038/s41467-017-02191-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02191-y</ArticleId><ArticleId IdType="pmc">PMC5715147</ArticleId><ArticleId IdType="pubmed">29203865</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Moynihan KD, Zheng Y, Szeto GL, Li AV, Huang B, et al. . Structure-Based Programming of Lymph-Node Targeting in Molecular Vaccines. Nature (2014) 507(7493):519&#x2013;22. doi:&#xa0;10.1038/nature12978</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12978</ArticleId><ArticleId IdType="pmc">PMC4069155</ArticleId><ArticleId IdType="pubmed">24531764</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Xue J, Chen W, Bai S, Zheng T, He C, et al. . Albumin-Biomineralized Nanoparticles to Synergize Phototherapy and Immunotherapy Against Melanoma. J Control Release (2020) 322:300&#x2013;11. doi:&#xa0;10.1016/j.jconrel.2020.03.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.03.045</ArticleId><ArticleId IdType="pubmed">32240675</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>